nach oben

Diabetologia

Erschienen in:

22.08.2018 | Editorial

The bark giving diabetes therapy some bite: the SGLT inhibitors

verfasst von: Sally M. Marshall

Erschienen in: Diabetologia | Ausgabe 10/2018

Einloggen, um Zugang zu erhalten

Excerpt

Following on from the success of last year’s special edition of Diabetologia, celebrating 60 years’ clinical use of metformin, for this year’s special edition we have chosen to focus on the newest class of glucose-lowering agents, the sodium–glucose cotransporter (SGLT) inhibitors. The 2015 update to the 2012 joint position statement from the EASD and the ADA suggested that metformin was in general the optimal first-line glucose-lowering agent, and, based on their beneficial effects on glucose, weight and blood pressure, placed the SGLT inhibitors as second- or third-line agents, together with all the other classes [1]. The statement pointed out that data on microvascular and macrovascular outcomes were lacking for almost all agents. Since then, new evidence has accumulated, particularly for the SGLT2 inhibitors, which has delighted us and challenged us to rethink our approach to glucose lowering in type 2 diabetes. …

Inzucchi SE, Bergenstal RM, Buse JB et al (2015) Management of hyperglycaemia in type 2 diabetes, 2015: a patient-centred approach. Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia 58:429–442CrossRefPubMed

Marshall SM (2017) 60 years of metformin use: a glance at the past and a look to the future. Diabetologia 60:1561–1565CrossRefPubMed

Kahn SE, Buse JB (2015) Medications for type 2 diabetes: how will we be treating patients in 50 years? Diabetologia 58:1735–1739CrossRefPubMedPubMedCentral

Ahren B (2015) Creative use of novel glucose-lowering drugs for type 2 diabetes: where will we head in the next 50 years? Diabetologia 58:1740–1744CrossRefPubMed

Cefalu WT, Stenlof K, Leiter LA et al (2015) Effects of canagliflozin on body weight and relationship to HbA_1c and blood pressure changes in patients with type 2 diabetes. Diabetologia 58:1183–1187CrossRefPubMedPubMedCentral

Zinman B, Wanner C, Lachin JM et al (2015) Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. New Engl J Med 373:2117–2128CrossRefPubMed

Neal B, Perkovic V, Mahaffey KW et al (2017) Canagliflozin and cardiovascular and renal events in type 2 diabetes. New Engl J Med 377:644–657CrossRefPubMed

Kosiborod M, Cavender MA, Fu AZ et al (2017) Lower risk of heart failure and death in patients initiated on sodium-glucose cotransporter-2 inhibitors versus other glucose-lowering drugs: the CVD-REAL Study (Comparative Effectiveness of Cardiovascular Outcomes in New Users of Sodium-Glucose Cotransporter-2 Inhibitors). Circulation 136:249–259CrossRefPubMedPubMedCentral

Fioretto P, Stefansson F, Johnsson E, Cain VA, Sjostrom CD (2016) Dapagliflozin reduces albuminuria over 2 years in patients with type 2 diabetes mellitus and renal impairment. Diabetologia 59:2036–2039CrossRefPubMedPubMedCentral

10.

Cherney D, Lund SS, Perkins BA et al (2016) The effect of sodium glucose cotransporter 2 inhibition with empagliflozin on microalbuminuria and macroalbuminuria in patients with type 2 diabetes. Diabetologia 59:1860–1870CrossRefPubMed

11.

Himsworth HP (1931) The relation of glycosuria to glycaemia and the determination of the renal threshold for glucose. Biochem J 25:1128–1146CrossRefPubMedPubMedCentral

12.

Hjärne U (1927) A study of orthoglycaemic glycosuria with particular reference to its hereditability. Acta Med Scand 67:422–494

13.

Poulsson LT (1930) On the mechanism of sugar elimination in phlorrhizin glycosuria. A contribution to the filtration-reabsorption theory on kidney function. J Physiol 69:411–422CrossRefPubMedPubMedCentral

14.

von Mering J (1886) Über experimentellen Diabetes; Verhandlungen des V Congresses für Innere Medizin in Wiesbaden J F Bergmann, Wiesbaden, 1-7 ( in German)

15.

Minkowski O (1892) Weitere Mittheilungen über den Diabetes mellitus nach Exstirpation des Pankreas. Berliner klin Wochenschr 29:90–93

16.

Rieg T, Vallon V (2018) Development of SGLT1 and SGLT2 inhibitors. Diabetologia. https://doi.org/10.1007/s00125-018-4654-7

17.

Ghezzi C, Loo DDF, Wright EM (2018) Physiology of renal glucose handling via SGLT1, SGLT2 and GLUT2. Diabetologia. https://doi.org/10.1007/s00125-018-4656-5

18.

Vallon V, Thomson SC (2017) Targeting renal glucose reabsorption to treat hyperglycaemia: the pleiotropic effects of SGLT2 inhibition. Diabetologia 60:215–225CrossRefPubMed

19.

Thomas MC, Cherney DZI (2018) The actions of SGLT2 inhibitors on metabolism, renal function and blood pressure. Diabetologia. https://doi.org/10.1007/s00125-018-4669-0

20.

Sattar N, McLaren J, Kristensen SL, Preiss D (2016) McMurray JJ. SGLT2 inhibition and cardiovascular events: why did EMPA-REG outcomes surprise and what were the likely mechanisms? Diabetologia 59:1333–1339CrossRefPubMedPubMedCentral

21.

Verma S, McMurray JJV (2018) SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review. Diabetologia. https://doi.org/10.1007/s00125-018-4670-7

22.

Baartscheer A, Schumacher CA, Wurst RCI et al (2018) Empagliflozin decreases myocardial cytoplasmic Na⁺ through inhibition of the cardiac Na⁺/H⁺ exchanger in rats and rabbits. Diabetologia 2017 60:568–573

23.

Uthman L, Baaercheer A, Bleijlevens B et al (2018) Class effects of SGLT2 inhibitors in mouse cardiomyocytes and hearts: inhibition of Na⁺/H⁺ exchanger, lowering of cytosolic Na⁺ and vasodilation. Diabetologia 61:722–726CrossRefPubMed

24.

Vettor R, Inzucchi SE, Fioretto P (2017) The cardiovascular benefits of empagliflozin: SGLT2-dependent and -independent effects. Diabetologia 60:395–398CrossRefPubMed

25.

Han JH, Oh TJ, Lee G et al (2017) The beneficial effects of empagliflozin, an SGLT2 inhibitor, on atherosclerosis in ApoE ^−/− mice fed a western diet. Diabetologia 60:364–376CrossRefPubMed

26.

Lupsa BC, Inzucchi SE (2018) Use of SGLT2 inhibitors in type 2 diabetes: weighing the risks and benefits. Diabetologia. https://doi.org/10.1007/s00125-018-4663-6

27.

McCrimmon RJ, Henry RR (2018) SGLT inhibitor adjunct therapy in type 1 diabetes. Diabetologia. https://doi.org/10.1007/s00125-018-4671-6

28.

Wanner C, Marx N (2018) SGLT2 inhibitors: the future for treatment of type 2 diabetes mellitus and other chronic diseases. Diabetologia. https://doi.org/10.1007/s00125-018-4678-z

29.

Thomsen SK, Gloyn AL (2017) Human genetics as a model for target validation: finding new therapies for diabetes. Diabetologia 60:960–970CrossRefPubMedPubMedCentral

30.

Fadini GP, Bonora BM, Avogaro A (2017) SGLT2 inhibitors and diabetic ketoacidosis: data from the FDA Adverse Event Reporting System. Diabetologia 60:1385–1389CrossRefPubMed

31.

Pedersen O, Oellgaard J, Gæde P et al (2018) Reduced risk of heart failure with intensified multifactorial intervention in individuals with type 2 diabetes and microalbuminuria: 21 years of follow-up in the randomised Steno-2 study. Diabetologia. https://doi.org/10.1007/s00125-018-4642-y

32.

Tang H, Dai Q, Shi W, Zhai S, Song Y, Han J (2017) SGLT2 inhibitors and risk of cancer in type 2 diabetes: a systematic review and meta-analysis of randomised controlled trials. Diabetologia 60:1862–1872CrossRefPubMed

33.

Tang H, Zhang X, Zhang J et al (2016) Elevated serum magnesium associated with SGLT2 inhibitor use in type 2 diabetes patients: a meta-analysis of randomised controlled trials. Diabetologia 59:2546–2551CrossRefPubMed

34.

Wilding JPH (2018) Medication use for the treatment of diabetes in obese individuals. Diabetologia 61:265–272CrossRefPubMed

35.

Eriksson JW, Lundkvist P, Jansson P-A et al (2018) Effects of dapagliflozin and n-3 carboxylic acids on non-alcoholic fatty liver disease in patients with type 2 diabetes. Diabetologia. https://doi.org/10.1007/s00125-018-4675-2

Titel: The bark giving diabetes therapy some bite: the SGLT inhibitors
verfasst von: Sally M. Marshall
Publikationsdatum: 22.08.2018
Verlag: Springer Berlin Heidelberg
Erschienen in: Diabetologia / Ausgabe 10/2018
Print ISSN: 0012-186X
Elektronische ISSN: 1432-0428
DOI: https://doi.org/10.1007/s00125-018-4673-4

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

25.04.2024 Allergien und Intoleranzreaktionen Nachrichten

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 10/2018

Development of SGLT1 and SGLT2 inhibitors

Use of SGLT2 inhibitors in type 2 diabetes: weighing the risks and benefits

Gluten intake and risk of type 2 diabetes in three large prospective cohort studies of US men and women

Sex differences in the association between diabetes and cancer: a systematic review and meta-analysis of 121 cohorts including 20 million individuals and one million events

Identification of a missense variant in the WFS1 gene that causes a mild form of Wolfram syndrome and is associated with risk for type 2 diabetes in Ashkenazi Jewish individuals